{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:11Z","timestamp":1792800251818,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00415-023-12016-2","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:01:56Z","timestamp":1699034516000},"page":"564-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Weaning and extubation failure in myasthenic crisis: a multicenter analysis"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-8616","authenticated-orcid":false,"given":"Bernhard","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-6711","authenticated-orcid":false,"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sch\u00f6nenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-8290","authenticated-orcid":false,"given":"Stefan T.","family":"Gerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen B.","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Steinbrecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Dunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9641-0922","authenticated-orcid":false,"given":"Hauke","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9232-201X","authenticated-orcid":false,"given":"Christiane","family":"Schneider-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Alberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-4793","authenticated-orcid":false,"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Linker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"B\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-2145","authenticated-orcid":false,"given":"Henning R.","family":"Stetefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Initiative of German NeuroIntensive Trial Engagement (IGNITE)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"3","key":"12016_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1385\/NCC:3:3:189","volume":"3","author":"D Lacomis","year":"2005","unstructured":"Lacomis D (2005) Myasthenic crisis. Neurocrit Care 3(3):189\u2013194. https:\/\/doi.org\/10.1385\/NCC:3:3:189","journal-title":"Neurocrit Care"},{"issue":"5","key":"12016_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE et al (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48(5):1253\u20131260. https:\/\/doi.org\/10.1212\/WNL.48.5.1253","journal-title":"Neurology"},{"issue":"18","key":"12016_CR3","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548\u20131554. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a41211","journal-title":"Neurology"},{"issue":"5","key":"12016_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1183\/09031936.00010206","volume":"29","author":"JM Boles","year":"2007","unstructured":"Boles JM et al (2007) Weaning from mechanical ventilation. Eur Respir J 29(5):1033\u20131056. https:\/\/doi.org\/10.1183\/09031936.00010206","journal-title":"Eur Respir J"},{"key":"12016_CR5","unstructured":"German Respiratory Society, \u201cProlonged Weaning S2k-Guideline,\u201d no. 020, pp. 1\u2013172, 2019"},{"key":"12016_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00449-0","author":"T Pham","year":"2023","unstructured":"Pham T et al (2023) Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(22)00449-0","journal-title":"Lancet Respir Med"},{"issue":"2","key":"12016_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1164\/ajrccm.159.2.9803106","volume":"159","author":"A Esteban","year":"1999","unstructured":"Esteban A et al (1999) Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Am J Respir Crit Care Med 159(2):512\u2013518. https:\/\/doi.org\/10.1164\/ajrccm.159.2.9803106","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"12016_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/01823246-199910010-00011","volume":"53","author":"L Vallverd\u00fa","year":"1999","unstructured":"Vallverd\u00fa L, Calaf N, Stubirana M, Net A, Benito S, Mancebo I (1999) Clinical characteristics, respiratory functional parameters, and outcome of two-hour T-piece trial in patients weaning from mechanical ventilation. Pneumologie 53(4):247. https:\/\/doi.org\/10.1097\/01823246-199910010-00011","journal-title":"Pneumologie"},{"issue":"6","key":"12016_CR9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1097\/CCM.0b013e31821209a8","volume":"39","author":"P Pelosi","year":"2011","unstructured":"Pelosi P et al (2011) Management and outcome of mechanically ventilated neurologic patients. Crit Care Med 39(6):1482\u20131492. https:\/\/doi.org\/10.1097\/CCM.0b013e31821209a8","journal-title":"Crit Care Med"},{"issue":"12","key":"12016_CR10","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201208-1523CI","volume":"187","author":"AW Thille","year":"2013","unstructured":"Thille AW, Richard JCM, Brochard L (2013) The decision to extubate in the intensive care unit. Am J Respir Crit Care Med 187(12):1294\u20131302. https:\/\/doi.org\/10.1164\/rccm.201208-1523CI","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"12016_CR11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archneur.65.7.929","volume":"65","author":"J Seneviratne","year":"2008","unstructured":"Seneviratne J, Mandrekar J, Wijdicks EFM, Rabinstein AA (2008) Predictors of extubation failure in myasthenic crisis. Arch Neurol 65(7):929\u2013933. https:\/\/doi.org\/10.1001\/archneur.65.7.929","journal-title":"Arch Neurol"},{"issue":"1","key":"12016_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12028-008-9139-y","volume":"10","author":"JY Wu","year":"2009","unstructured":"Wu JY, Kuo PH, Fan PC, Wu HD, Shih FY, Yang PC (2009) The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care 10(1):35\u201342. https:\/\/doi.org\/10.1007\/s12028-008-9139-y","journal-title":"Neurocrit Care"},{"key":"12016_CR13","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:3:3:213","author":"AA Rabinstein","year":"2005","unstructured":"Rabinstein AA, Mueller-Kronast N (2005) Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. https:\/\/doi.org\/10.1385\/NCC:3:3:213","journal-title":"Neurocrit Care"},{"key":"12016_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-010-9369-7","author":"CD Anderson","year":"2011","unstructured":"Anderson CD et al (2011) Neurologic examination and extubation outcome in the neurocritical care unit. Neurocrit Care. https:\/\/doi.org\/10.1007\/s12028-010-9369-7","journal-title":"Neurocrit Care"},{"key":"12016_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112198","author":"S Wang","year":"2014","unstructured":"Wang S, Zhang L, Huang K, Lin Z, Qiao W, Pan S (2014) Predictors of extubation failure in neurocritical patients identified by a systematic review and meta-analysis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0112198","journal-title":"PLoS ONE"},{"issue":"6","key":"12016_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1055\/s-0037-1608773","volume":"38","author":"J B\u00f6sel","year":"2017","unstructured":"B\u00f6sel J (2017) Who is safe to extubate in the neuroscience intensive care unit? Semin Respir Crit Care Med 38(6):830\u2013839. https:\/\/doi.org\/10.1055\/s-0037-1608773","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"12016_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/ALN.0000000000001379","volume":"126","author":"T Godet","year":"2017","unstructured":"Godet T et al (2017) Extubation failure in brain-injured patients. Anesthesiology 126(1):104\u2013114. https:\/\/doi.org\/10.1097\/ALN.0000000000001379","journal-title":"Anesthesiology"},{"issue":"6","key":"12016_CR18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0300060516669893","volume":"44","author":"Z Liu","year":"2016","unstructured":"Liu Z et al (2016) Predictors of extubation outcomes following myasthenic crisis. J Int Med Res 44(6):1524\u20131533. https:\/\/doi.org\/10.1177\/0300060516669893","journal-title":"J Int Med Res"},{"issue":"1","key":"12016_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1378\/chest.112.1.186","volume":"112","author":"SK Epstein","year":"1997","unstructured":"Epstein SK, Ciubotaru RL, Wong JB (1997) Effect of failed extubation on the outcome of mechanical ventilation. Chest 112(1):186\u2013192. https:\/\/doi.org\/10.1378\/chest.112.1.186","journal-title":"Chest"},{"issue":"3","key":"12016_CR20","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B et al (2020) Myasthenic crisis demanding mechanical ventilation. Neurology 94(3):e299\u2013e313. https:\/\/doi.org\/10.1212\/WNL.0000000000008688","journal-title":"Neurology"},{"key":"12016_CR21","unstructured":"Wiendl H (2012) Diagnostik und Therapie der Myasthenia gravis und des Lambert- \u00ad Eaton- \u00ad Syndroms Die wichtigsten Empfehlungen auf einen Blick Definition und Klassifikation,\u201d DGN Leitlinien, pp. 1\u201360"},{"issue":"8","key":"12016_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the german neurological society. J Neurol 263(8):1473\u20131494. https:\/\/doi.org\/10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"12016_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/0885066620967646","author":"K Angstwurm","year":"2020","unstructured":"Angstwurm K et al (2020) Early tracheostomy is associated with shorter ventilation time and duration of ICU stay in patients with myasthenic crisis\u2014a multicenter analysis. J Intensive Care Med. https:\/\/doi.org\/10.1177\/0885066620967646","journal-title":"J Intensive Care Med"},{"issue":"12","key":"12016_CR24","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1097\/00003246-200212000-00009","volume":"30","author":"PN Varelas","year":"2002","unstructured":"Varelas PN et al (2002) Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med 30(12):2663\u20132668. https:\/\/doi.org\/10.1097\/00003246-200212000-00009","journal-title":"Crit Care Med"},{"issue":"9A","key":"12016_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1590\/0004-282X20130108","volume":"71","author":"DA Godoy","year":"2013","unstructured":"Godoy DA, De Mello LJV, Masotti L, Di Napoli M (2013) The myasthenic patient in crisis: an update of the management in neurointensive care unit. Arq Neuropsiquiatr 71(9A):627\u2013639. https:\/\/doi.org\/10.1590\/0004-282X20130108","journal-title":"Arq Neuropsiquiatr"},{"issue":"8","key":"12016_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00134-013-2960-6","volume":"39","author":"MS Damian","year":"2013","unstructured":"Damian MS et al (2013) The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barr\u00e9 syndrome admitted to critical care\u202f: an analysis of the Intensive Care National Audit & Research. Intensive Care Med 39(8):1405\u20131412. https:\/\/doi.org\/10.1007\/s00134-013-2960-6","journal-title":"Intensive Care Med"},{"key":"12016_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.3.629","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI et al (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. https:\/\/doi.org\/10.1212\/wnl.52.3.629","journal-title":"Neurology"},{"key":"12016_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000119","author":"P Ortiz-Salas","year":"2016","unstructured":"Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez JH (2016) Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. https:\/\/doi.org\/10.1097\/CND.0000000000000119","journal-title":"J Clin Neuromuscul Dis"},{"key":"12016_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub3","author":"P Gajdos","year":"2008","unstructured":"Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002277.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"12016_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315690","author":"C Antozzi","year":"1991","unstructured":"Antozzi C et al (1991) A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. https:\/\/doi.org\/10.1007\/BF00315690","journal-title":"J Neurol"},{"key":"12016_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12444","author":"S \u017divkovi\u0107","year":"2016","unstructured":"\u017divkovi\u0107 S (2016) Intravenous immunoglobulin in the treatment of neurologic disorders. Acta Neurol Scand. https:\/\/doi.org\/10.1111\/ane.12444","journal-title":"Acta Neurol Scand"},{"key":"12016_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000116","author":"M Ballow","year":"2014","unstructured":"Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol. https:\/\/doi.org\/10.1097\/ACI.0000000000000116","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"23","key":"12016_CR33","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12016-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12016-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12016-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:18:46Z","timestamp":1704471526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12016-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["12016"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12016-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernhard Neumann reports no disclosures; Klemens Angstwurm reports travel support (until 2014) from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis, Teva and honoria from Biogen und TEVA; moreover he has been principal investigatore in studies in neuroimmunology sponsored by Alexion, Bayer, Biogen, Chugay, MerckSerono, Novartis, and Roche; all not related to the present study; Christian Dohmen reports no disclosures; Philipp Mergenthaler is on the Advisory Board of HealthNextGen Inc. and has equity interest in the company, within the scope of the present work, but not directly related; Siegfried Kohler reports no disclosures; Silvia Sch\u00f6nenberger reports no disclosures; De-Hyung Lee reports no disclosures; Stefan T. Gerner reports no disclosures; Hagen B. Huttner reports personal fees from Daiichi Sanyko, grants and personal fees from Novartis, grants and personal fees from UCB Pharma, grants and personal fees from Portola Pharmaceuticals, personal fees from Bayer AG, personal fees from Boehringer Ingelheim, personal fees from Prediction BioSciences, outside the submitted work; Andrea Thieme reports no disclosures; Andreas Steinbrecher reports no disclosures; Juliane Dunkel reports no disclosures; Christian Roth reports no disclosures; Hauke Schneider reports no disclosures; Heinz Reichmann reports no disclosures; Hannah Fuhrer reports no disclosures; Ingo Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, grants and personal fees from Chugai, personal fees from IQVIA, outside the submitted work; Christiane Schneider-Gold has received speaker \u2018s and consulting honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Argenx, Bayer Vital, Hormosan Pharma, Immunovant, Janssen, Lupin Pharmaceuticals, Roche, Sanofi-Genzyme, Teva (2017) and UCB Pharma. Travel grant from Alexion. All outside the submitted work; Anke Alberty reports no disclosures; Jan Zinke reports no disclosures; Michael Schroeter reports personal fees from Alexion, Argenx, Bayer, Biogen, Datamed, Gilead, Grifols, Merck, Novartis, Roche, Sanofi, Teva, UCB outside the submitted work.; Ralf Linker reports no disclosures; Andreas Meisel reports financial research support (paid to his institution) and personal fees from Alexion, AstraZeneca Rare Disease, financial research support (paid to his institution) and personal fees from argenx, personal fees from Grifols, personal fees from Hormosan, personal fees from Janssen, personal fees from Merck, personal fees from Novartis, financial research support (paid to his institution) from Octapharma, personal fees from UCB, outside the submitted work. He is chairman of the medical advisory board of the German Myasthenia Gravis Society; Julian B\u00f6sel reports personal fees from Medtronic, personal fees from Zoll, personal fees from Boehringer Ingelheim, personal fees from Sedana Medical, personal fees from PCORI outside the submitted work; Henning R Stetefeld reports no disclosures. Statistical Analysis conducted by Dr. Bernhard Neumann, University Medical Center Regensburg\/Donau-Isar-Klinikum Deggendorf. The authors declare no financial or other conflicts of interest related to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No: 15-101-0259). Due to the retrospective character of the study patient\u2019s consent was not necessary according to the decisions of the ethic committees and institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}